NASDAQ:JSPR Jasper Therapeutics (JSPR) Stock Price, News & Analysis $0.50 +0.01 (+1.09%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$0.50 -0.01 (-1.00%) As of 10/14/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Jasper Therapeutics Stock (NASDAQ:JSPR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Jasper Therapeutics alerts:Sign Up Key Stats Today's Range$0.46▼$0.5250-Day Range$0.50▼$0.8952-Week Range$0.32▼$2.69Volume620,088 shsAverage Volume373,888 shsMarket Capitalization$16.67 millionP/E RatioN/ADividend YieldN/APrice Target$7.33Consensus RatingHold Company Overview Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapies for diseases involving the hematopoietic system, including conditions that require the replacement or modification of blood-forming stem cells. The company’s approach is designed to address biological barriers that can limit stem-cell transplantation, gene therapy and the treatment of mast cell–driven diseases. Jasper’s lead product candidate is briquilimab, formerly known as JSP191, an investigational monoclonal antibody that targets CD117, a receptor found on hematopoietic stem cells and mast cells. By blocking CD117, briquilimab is intended to reduce or remove existing stem cells and mast cells, potentially creating space for transplanted or genetically modified cells while reducing the need for intensive chemotherapy-based conditioning. The company has evaluated briquilimab in clinical programs involving hematopoietic stem-cell transplantation and gene therapy, as well as diseases associated with abnormal mast-cell activity, including chronic urticaria. Jasper Therapeutics is headquartered in Redwood City, California, and conducts development activities through clinical studies and collaborations in the United States and other regions. Its products remain investigational and have not been established as approved therapies based on the company’s publicly described pipeline.AI Generated. May Contain Errors. Read More Jasper Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreJSPR MarketRank™: 1.954060813475 of 5 starsJasper Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 726th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingJasper Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialJasper Therapeutics has a consensus price target of $7.33, representing about 1,363.7% upside from its current price of $0.50.Amount of Analyst CoverageJasper Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Jasper Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Jasper Therapeutics are expected to grow in the coming year, from ($1.14) to ($0.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jasper Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jasper Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJasper Therapeutics has a P/B Ratio of 3.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Jasper Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.45% of the float of Jasper Therapeutics has been sold short.Short Interest Ratio / Days to CoverJasper Therapeutics has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.Change versus previous monthShort interest in Jasper Therapeutics has recently increased by 7.06%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJasper Therapeutics does not currently pay a dividend.Dividend GrowthJasper Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.47 News SentimentJasper Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Jasper Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for JSPR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Jasper Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Jasper Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders3.90% of the stock of Jasper Therapeutics is held by insiders.Percentage Held by Institutions79.85% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Jasper Therapeutics' insider trading history. Receive JSPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JSPR Stock News HeadlinesJasper Therapeutics, Inc. (NASDAQ:JSPR) Stock Has Consensus Target Price of $7.33 According to AnalystsOctober 13 at 4:46 AM | americanbankingnews.comJasper Therapeutics (NASDAQ:JSPR) Stock Price Down 2.7% - Here's What HappenedOctober 13 at 1:43 AM | americanbankingnews.comBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses. | Decentralized Masters (Ad)Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding WarrantsOctober 7, 2026 | globenewswire.comJasper Therapeutics Stockholders Approve Capital Structure FlexibilityOctober 5, 2026 | tipranks.comJasper Therapeutics Announces Key Regulatory and Clinical AppointmentsSeptember 15, 2026 | globenewswire.comJasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 9, 2026 | globenewswire.comJasper Therapeutics, Inc.: Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 15, 2026 | finanznachrichten.deSee More Headlines JSPR Stock Analysis - Frequently Asked Questions How have JSPR shares performed this year? Jasper Therapeutics' stock was trading at $1.83 at the beginning of the year. Since then, JSPR shares have decreased by 72.6% and is now trading at $0.5010. How were Jasper Therapeutics' earnings last quarter? Jasper Therapeutics, Inc. (NASDAQ:JSPR) released its earnings results on Friday, August, 14th. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.17. When did Jasper Therapeutics' stock split? Jasper Therapeutics's stock reverse split before market open on Thursday, January 4th 2024.The 1-10 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Jasper Therapeutics? Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Jasper Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Jasper Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Tesla (TSLA), Micron Technology (MU), Definium Therapeutics (DFTX) and Intel (INTC). Company Calendar Last Earnings8/14/2026Today10/14/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 2 days ago, JSPR's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:JSPR CIK1788028 Webjaspertherapeutics.com Phone650-549-1400FaxN/AEmployees22Year FoundedN/APrice Target and Rating Average Price Target for Jasper Therapeutics$7.33 High Price Target$17.00 Low Price Target$2.00 Potential Upside/Downside+1,363.7%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$75.80 million Net MarginsN/A Pretax MarginN/A Return on Equity-884.17% Return on Assets-143.83% Debt Debt-to-Equity RatioN/A Current Ratio1.48 Quick Ratio1.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book3.34Miscellaneous Outstanding Shares33,280,000Free Float31,977,000Market Cap$16.67 million OptionableOptionable Beta3.16 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:JSPR) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
